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Introduction: 
Dantrolene is neuroprotective in animal models and may attenuate cerebral vasospasm (cVSP) after 
aneurysmal subarachnoid hemorrhage (aSAH) in humans. We evaluated safety/tolerability and feasibility of 
intravenous dantrolene (IV-D) after aSAH. 
 
Methods: 
In this single-center, randomized, double blind, placebo-controlled trial, 31 patients with acute aSAH were 
randomized to IV-D 1.25 mg IV every 6 hours x 7 days (n=16) or placebo (n=15). Primary endpoint was incidence 
of hyponatremia (sNa ≤ 134 mmol/L) and liver toxicity (% patients with ALT, AST and AlkPhos >5x upper limit of 
normal). Secondary safety endpoints included tolerability, systemic hypotension and intracranial hypertension. 
Efficacy was explored by clinical, transcranial Doppler (TCD) or angiographic cVSP occurrence, delayed cerebral 
ischemia (DCI) and 3-month modified-Rankin-Scale, Glasgow Outcome Scale and Barthel Index. Statistical 
analysis was performed using non-parametric tests, generalized estimating equations and mixed models. 
 
Results: 
Between IV-D vs. placebo, no differences were observed in the primary outcome (hyponatremia: 44% vs. 67% 
[p=0.29]; liver toxicity 6% vs. 0% [p=1.0]). Numerically more AEs and SAEs were seen in the IV-D group, but 
did not reach statistical significance (16 vs. 5 AEs, of which 5 vs. 2 were severe; RR 2.2; 95% CI 0.7-6.7; 
p=0.16). Three IV-D vs. two placebo patients reached stop criteria: one IV-D patient developed liver toxicity; 
two patients in each group developed brain edema requiring osmotherapy. No differences in angiographic, 
TCD, clinical cVSP, DCI, or 3-month functional outcomes were seen. Quantitative angiogram analysis revealed 
a trend towards increased vessel diameters in the IV-D group after the 7-day infusion-period (p=0.05). 
 
Conclusions:  
In this small trial, IV-Dantrolene after aSAH was feasible, tolerable and safe, but was underpowered to show 
efficacy or outcome differences. 
 
Clinical Trial Registration Information: http://clinicaltrials.gov NCT01024972 
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